- Home
- CBT
as 05-30-2025 4:00pm EST
Cabot Corp manufactures and sells a variety of chemicals, materials, and chemical-based products. The company organizes itself into two segments based on the product type. The reinforcement materials segment, which generates more revenue than any other segment, sells rubber-grade carbon black products used in hoses and belts in automobiles. The performance chemicals segment sells ink-jet colorants and metal oxides used in the automotive and construction industries.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 4.3B | IPO Year: | N/A |
| Target Price: | $92.67 | AVG Volume (30 days): | 509.7K |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.72 | EPS Growth: | -2.20 |
| 52 Week Low/High: | $71.64 - $117.46 | Next Earning Date: | 05-05-2025 |
| Revenue: | $3,908,000,000 | Revenue Growth: | -0.05% |
| Revenue Growth (this year): | -3.36% | Revenue Growth (next year): | 3.45% |
Latest Cabot Corporation News
CBT Breaking Stock News: Dive into CBT Ticker-Specific Updates for Smart Investing
Simply Wall St.
6 days ago
Should You Buy Cabot Corporation (NYSE:CBT) For Its Upcoming Dividend?
Argus Research
11 days ago
CBT: Lowering target price to $79.00
Oilprice.com
17 days ago
Tech Breakthrough Could Upend the $650 Billion Plastics Market
Argus Research
18 days ago
CBT: Raising target price to $80.00
Simply Wall St.
22 days ago
Cabot (NYSE:CBT) Has Announced That It Will Be Increasing Its Dividend To $0.45
Zacks
22 days ago
Cabot's Earnings Surpass Estimates in Q2, Revenues Miss
Simply Wall St.
24 days ago
Cabot Second Quarter 2025 Earnings: EPS: US$1.74 (vs US$1.50 in 2Q 2024)
GuruFocus.com
25 days ago
Cabot Corp (CBT) Q2 2025 Earnings Call Highlights: Strong EPS Growth Amidst Mixed Segment ...
Compare CBT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CBT Cabot Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.